{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:28:47Z","timestamp":1793744927067,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101286","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:32:30Z","timestamp":1789169550000},"page":"101286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ablative magnetic resonance\u2013guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity"],"prefix":"10.1016","volume":"62","author":[{"given":"John S.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Goodchild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyak","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Michael","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintallah","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kujtim","family":"Latifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell F.","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctro.2026.101286_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.ctro.2026.101286_bb0010","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/cancers14082028","article-title":"Advances in the diagnosis and therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)","volume":"14","author":"Kaliszewski","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ctro.2026.101286_bb0015","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","article-title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study","volume":"28","author":"Pavel","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2026.101286_bb0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s11912-024-01559-w","article-title":"Current Management of Neuroendocrine Tumour Liver Metastases","volume":"26","author":"Sharma","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctro.2026.101286_bb0025","author":"Eads"},{"issue":"4","key":"10.1016\/j.ctro.2026.101286_bb0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctro.2026.101286_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179445","article-title":"Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms","volume":"12","author":"Panzuto","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ctro.2026.101286_bb0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-18-0462","article-title":"Local treatment for focal progression in metastatic neuroendocrine tumors","volume":"26","author":"Al-Toubah","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctro.2026.101286_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_389278","article-title":"Therapy sequencing in patients with advanced neuroendocrine neoplasms","author":"Riechelmann","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"issue":"9","key":"10.1016\/j.ctro.2026.101286_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101286_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000514914","article-title":"Stereotactic ablative radiotherapy for the Management of Liver Metastases from neuroendocrine neoplasms: a preliminary study","volume":"112","author":"Hudson","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"10022","key":"10.1016\/j.ctro.2026.101286_bb0060","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ctro.2026.101286_bb0065","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101286_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctro.2026.101286_bb0075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with Capecitabine and Temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2026.101286_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctro.2026.101286_bb0085","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101286_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","article-title":"Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival","volume":"40","author":"Chen","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101286_bb0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.sla.0000171032.99149.fe","article-title":"Local recurrence after hepatic radiofrequency coagulation","volume":"242","author":"Mulier","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctro.2026.101286_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-024-03538-w","article-title":"Prospective study on stereotactic body radiotherapy for small pancreatic neuroendocrine tumors: tolerance and effectiveness analysis","author":"L\u00f3pez Gonzalez","year":"2024","journal-title":"Clin Transl Oncol[Internet]"},{"issue":"4","key":"10.1016\/j.ctro.2026.101286_bb0105","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2023.01.028","article-title":"Early-stage primary lung neuroendocrine tumors treated with stereotactic body radiation therapy: a multi-institution experience","volume":"116","author":"Oliver","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101286_bb0110","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.ijrobp.2023.06.2388","article-title":"Single institutional experience using radiation therapy in the treatment of neuroendocrine tumor primary and metastatic lesions","volume":"117","author":"Qualls","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2026.101286_bb0115","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.prro.2022.07.001","article-title":"A Practical Workflow for Magnetic Resonance\u2013Guided Stereotactic Body Radiation Therapy to the Pancreas","volume":"13","author":"Sim","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101286_bb0120","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101286_bb0125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline Resectable and locally advanced pancreatic Cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.ctro.2026.101286_bb0130","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1002\/cam4.4139","article-title":"Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis","volume":"10","author":"Yoon","year":"2021","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.ctro.2026.101286_bb0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101286_bb0140","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1245\/s10434-023-13372-z","article-title":"Survival and symptomatic relief after Cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term follow-up evaluation of more than 500 patients","volume":"30","author":"Gudmundsdottir","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101286_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival","volume":"142","author":"Mazzaglia","year":"2007","journal-title":"Surgery"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:03:57Z","timestamp":1793743437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":29,"alternative-id":["S2405630826001813"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101286","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ablative magnetic resonance\u2013guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101286"}}